KDR and adenocarcinoma: Comprehensive safety and pharmacokinetic data for bemarituzumab demonstrated immune-mediated synergy across all three antibodies, and strategies to overcome adaptive resistance, particularly through ramucirumab and dual VEGF-A/VEGFR2 inhibition, collectively support their continued clinical development, especially in combination regimens aimed at optimizing durable responses in advanced G/GEJ adenocarcinomas.